Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 7
1981 6
1982 7
1983 10
1984 8
1985 6
1986 7
1987 2
1988 4
1989 2
1990 1
1991 3
1993 1
1994 3
1995 8
1996 7
1997 3
1998 8
1999 7
2000 2
2001 11
2002 8
2003 7
2004 9
2005 10
2006 9
2007 6
2008 13
2009 26
2010 30
2011 20
2012 20
2013 11
2014 16
2015 18
2016 20
2017 11
2018 7
2019 8
2020 9
2021 10
2022 10
2023 8
2024 4
2025 8
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

382 results

Results by year

Filters applied: . Clear all
Page 1
Fenofibric acid.
Rath NP, Haq W, Balendiran GK. Rath NP, et al. Acta Crystallogr C. 2005 Feb;61(Pt 2):o81-4. doi: 10.1107/S0108270104032573. Epub 2005 Jan 15. Acta Crystallogr C. 2005. PMID: 15695917
Unlike the related fenofibrate molecule [Henry, Zhang, Gao & Bruckner (2003). Acta Cryst. E59, o699-o700], fenofibric acid {systematic name: 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid}, C17H15ClO4, contains a carboxylic acid moiety instead of an ester …
Unlike the related fenofibrate molecule [Henry, Zhang, Gao & Bruckner (2003). Acta Cryst. E59, o699-o700], fenofibric acid …
Lipid-lowering drugs.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Feb 11;61(1565):17-24. Med Lett Drugs Ther. 2019. PMID: 30845106 No abstract available.
Fenofibric acid for hyperlipidemia.
Saurav A, Kaushik M, Mohiuddin SM. Saurav A, et al. Expert Opin Pharmacother. 2012 Apr;13(5):717-22. doi: 10.1517/14656566.2012.658774. Epub 2012 Mar 9. Expert Opin Pharmacother. 2012. PMID: 22404421 Review.
AREAS COVERED: This article reviews the role of fenofibric acid in the context of results from recent randomized trials on fenofibrate, including the ACCORD Trial. It discusses the current status of fenofibric acid in the management of dyslipidemia, es …
AREAS COVERED: This article reviews the role of fenofibric acid in the context of results from recent randomized trials on fen …
Fenofibric Acid (trilipix).
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2009 May 4;51(1311):33-4. Med Lett Drugs Ther. 2009. PMID: 19417718 No abstract available.
Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association.
Wiggins BS, Saseen JJ, Page RL 2nd, Reed BN, Sneed K, Kostis JB, Lanfear D, Virani S, Morris PB; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; and Council on Functional Genomics and Translational Biology. Wiggins BS, et al. Circulation. 2016 Nov 22;134(21):e468-e495. doi: 10.1161/CIR.0000000000000456. Epub 2016 Oct 17. Circulation. 2016. PMID: 27754879 Review. No abstract available.
PPAR-mediated reduction of lipid accumulation in hepatocytes involves the autophagy-lysosome-mitochondrion axis.
Cetti F, Ossoli A, Garavaglia C, Da Dalt L, Norata GD, Gomaraschi M. Cetti F, et al. Ann Med. 2025 Dec;57(1):2497112. doi: 10.1080/07853890.2025.2497112. Epub 2025 Apr 28. Ann Med. 2025. PMID: 40289698 Free PMC article.
METHODS: HepG2 cells were treated with oleate/palmitate (O/P) to induce lipid accumulation and exposed to the PPARalpha agonist fenofibric acid, the gamma agonist pioglitazone, the delta agonist seladelpar, or the dual alpha/gamma agonist saroglitazar. RESULTS: The …
METHODS: HepG2 cells were treated with oleate/palmitate (O/P) to induce lipid accumulation and exposed to the PPARalpha agonist fenofibri …
Update on fenofibrate.
Guay DR. Guay DR. Cardiovasc Drug Rev. 2002 Winter;20(4):281-302. doi: 10.1111/j.1527-3466.2002.tb00098.x. Cardiovasc Drug Rev. 2002. PMID: 12481201 Review.
Fenofibrate is a fibric acid derivative that has been marketed since the mid-1970's (1998 in the United States). Its active metabolite, fenofibric acid, is responsible for the primary pharmacodynamic effects of the drug: reductions in total plasma cholesterol, low d …
Fenofibrate is a fibric acid derivative that has been marketed since the mid-1970's (1998 in the United States). Its active metabolite, f …
Assessing the real-world safety of fenofibric acid for hyperlipidemia: results from WHO-VigiAccess and FAERS databases.
Li Y, Wang Y, Zhang J, Zhang R, Yao Z, Chen X, Xu X. Li Y, et al. Front Med (Lausanne). 2025 Nov 7;12:1702197. doi: 10.3389/fmed.2025.1702197. eCollection 2025. Front Med (Lausanne). 2025. PMID: 41282005 Free PMC article.
As a lipid-lowering agent, a comprehensive understanding of the real-world safety profile of fenofibric acid is essential to ensure its safe and effective use in clinical practice. METHODS: This study utilizes four disproportionality analysis methods to investigate …
As a lipid-lowering agent, a comprehensive understanding of the real-world safety profile of fenofibric acid is essential to e …
Fenofibric Acid Can Cause False-Positive Urine Methylenedioxymethamphetamine Immunoassay Results.
Quesada L, Gomila I, Fe A, Servera MA, Yates C, Morell-Garcia D, Castanyer B, Barceló B. Quesada L, et al. J Anal Toxicol. 2015 Nov-Dec;39(9):734-40. doi: 10.1093/jat/bkv074. Epub 2015 Jul 22. J Anal Toxicol. 2015. PMID: 26203185
We estimated that the addition of 225 g/mL pure fenofibric acid to blank urine would be sufficient to result in a positive DRI( ) Ecstasy Assay. ...This apparent discrepancy can be explained in several ways, one of them is that the beta-glucuronidase-resistent f …
We estimated that the addition of 225 g/mL pure fenofibric acid to blank urine would be sufficient to result in a positive DR …
Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Yang LP, Keating GM. Yang LP, et al. Am J Cardiovasc Drugs. 2009;9(6):401-9. doi: 10.2165/11203920-000000000-00000. Am J Cardiovasc Drugs. 2009. PMID: 19929038
Fenofibric acid activates peroxisome proliferator-activated receptor alpha to modify fatty acid and lipid metabolism. ...Once-daily fenofibric acid 135 mg plus a statin was generally as well tolerated as monotherapy with fenofibric acid 1 …
Fenofibric acid activates peroxisome proliferator-activated receptor alpha to modify fatty acid and lipid metabolism. ...Once- …
382 results